Regeneron Pharmaceuticals, Inc. (REGN)
Summary
Regeneron: Why I Still See Upside After The Rally
Regeneron Pharmaceuticals ends August on a high note. The decline in U.S. sales of Eylea following the launch of biosimilars is no longer putting pressure on REGN stock. That's because REGN's Dupixent sales reached €5.15 billion in the second quarter, up 23.6% sequentially.
REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
Regeneron's Eylea HD and Dupixent strength are fueling growth, while oncology gains and pipeline progress support its outlook.
Surging Earnings Estimates Signal Upside for Regeneron (REGN) Stock
Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Regeneron Pharmaceuticals, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 1,028 | $852,756.71 | $783,983.64 | -$68,773.07 | -8.06% |
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 75 | $52,367.24 | $57,197.25 | $4,830.01 | 9.22% |
 Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 14 | $10,816.96 | $10,676.82 | -$140.14 | -1.3% |
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 967 | $549,719.22 | $737,463.21 | $187,743.99 | 34.15% |
 Curtis Ellergodt Rothschild Investment LLC | 1,486 | $1.16M | $1.14M | -$19,357.25 | -1.67% |
Regeneron Pharmaceuticals, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| GR Gregory Renza Truist Securities | 5.46 | $4,067.14 | $3,798.45 | -$268.69 | -6.61% |
| RW Robert Wasserman Benchmark | 24.16 | $16,340.34 | $16,798.24 | $457.9 | 2.8% |
 Rajesh Kumar HSBC | 43.24 | $28,099.68 | $30,061.61 | $1,961.93 | 6.98% |
Regeneron Pharmaceuticals, Inc. (REGN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Regeneron Pharmaceuticals, Inc. ever had a stock split?
Regeneron Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Leonard S. Schleifer CEO | NASDAQ (NGS) Exchange | 75886F107 CUSIP |
| US Country | 15,410 Employees | 4 Jun 2026 Last Dividend | - Last Split | 2 Apr 1991 IPO Date |
Overview
Regeneron Pharmaceuticals, Inc. is a biotechnology firm that is renowned for its dedication to discovering, inventing, developing, manufacturing, and commercializing medicines to combat a variety of diseases globally. Since its inception in 1988, the company has been at the forefront of innovative treatments, striving to address the unmet medical needs of patients around the world. With its headquarters nested in Tarrytown, New York, Regeneron has made a significant impact in the pharmaceutical industry by delivering life-changing medicines to patients in need.
Products and Services
Regeneron Pharmaceuticals, Inc. offers a diverse portfolio of products aimed at treating a wide range of diseases, including but not limited to, eye diseases, allergies and inflammations, cardiovascular and metabolic conditions, infectious diseases, rare diseases, cancers, pain, and hematologic conditions.
- EYLEA Injection: Used for the treatment of wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity.
- Dupixent Injection: Offers relief for adults and children suffering from atopic dermatitis and asthma, targeting the underlying inflammation and immune system response.
- Libtayo Injection: Approved for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma, providing a much-needed option for patients with this serious skin cancer.
- Praluent Injection: Aimed at adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, this medication works by reducing LDL cholesterol levels.
- REGEN-COV: For patients with COVID-19, offering a treatment option to help reduce the severity of the disease and potential hospitalization.
- Kevzara Solution: Designed for adults with rheumatoid arthritis, Kevzara works by interfering with the inflammatory pathway to reduce symptoms and slow disease progression.
- Inmazeb Injection: The first FDA-approved treatment for infection caused by Zaire ebolavirus, offering hope to patients facing this deadly disease.
- ARCALYST Injection: Treats cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome, by targeting the body’s inflammatory response.
- ZALTRAP Injection: Used in combination with chemotherapy for the treatment of metastatic colorectal cancer, aiming to slow the spread of the disease.
In addition to these products, Regeneron is continuously working on developing new treatments for a variety of diseases, demonstrating their commitment to innovation and improving patient health worldwide.
